Entrada Therapeutics (TRDA) Income from Continuing Operations (2022 - 2025)
Historic Income from Continuing Operations for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$44.2 million.
- Entrada Therapeutics' Income from Continuing Operations fell 21575.19% to -$44.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.5 million, marking a year-over-year decrease of 28829.49%. This contributed to the annual value of $65.6 million for FY2024, which is 108780.3% up from last year.
- Per Entrada Therapeutics' latest filing, its Income from Continuing Operations stood at -$44.2 million for Q3 2025, which was down 21575.19% from -$43.1 million recorded in Q2 2025.
- Over the past 5 years, Entrada Therapeutics' Income from Continuing Operations peaked at $55.0 million during Q2 2024, and registered a low of -$44.2 million during Q3 2025.
- Moreover, its 4-year median value for Income from Continuing Operations was -$17.3 million (2025), whereas its average is -$9.4 million.
- In the last 5 years, Entrada Therapeutics' Income from Continuing Operations skyrocketed by 44948.68% in 2024 and then crashed by 21575.19% in 2025.
- Quarter analysis of 4 years shows Entrada Therapeutics' Income from Continuing Operations stood at -$24.6 million in 2022, then surged by 61.43% to -$9.5 million in 2023, then skyrocketed by 111.63% to $1.1 million in 2024, then crashed by 4098.19% to -$44.2 million in 2025.
- Its Income from Continuing Operations was -$44.2 million in Q3 2025, compared to -$43.1 million in Q2 2025 and -$17.3 million in Q1 2025.